Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares grows in line with its trailing trend
Q1 FY2026 weighted avg shares of 61.8M shares rose 0.9% year over year, in line with the +1.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +13.5% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.9% toward the trailing-twelve-month pace of +1.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 61.37M USD
- Year-over-year change
- +1.4%
- 4-year CAGR
- +14.4%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.37M | +1.4% |
| FY2024 | 2024-12-31 | 60.54M | +3.1% |
| FY2023 | 2023-12-31 | 58.72M | +39.8% |
| FY2022 | 2022-12-31 | 42.02M | +17.2% |
| FY2021 | 2021-12-31 | 35.85M | — |
Weighted Avg Shares vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's LTM Mar 2026 weighted avg shares of 61.49M shares is the 6th highest of the 10 companies compared; the peer median is 63.24M shares.
- Its year-over-year change of +1.3% is the 7th highest of 10, against a peer median of +4.8%.
- Over three fiscal years its annual growth of +13.5% compares with a peer median of +16.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 74.41M | +4.8% | +1.5% | |
| LTM Mar 2026 | 71.52M | +0.4% | +10.8% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | 68.95M | +154.8% | +40.1% |
| LTM Mar 2026 | 66.33M | +37.1% | +16.8% | |
| LTM Mar 2026 | 63.24M | +0.8% | +0.9% | |
| LTM Mar 2026 | 61.49M | +1.3% | +13.5% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | 24.5M | +1.8% | +11.6% |
| LTM Mar 2026 | 16.73M | +5.9% | +18.9% | |
| LTM Mar 2026 | 10.33M | +43.7% | +44.6% | |
| LTM Mar 2026 | 6.42M | -22.0% | +18.8% | |
| Peer median (excluding PLRX) | 63.24M | +4.8% | +16.8% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57M | 9.69M | 1.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.7M |
| Gross Profit | 7.57M | 9.69M | 1.58M | 0 | (1.7M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 77.55M | 96.94M | 127.8M | 169.31M | 109.16M |
| Selling, General & Admin | 27.56M | 39.95M | 57.93M | 59.06M | 47.22M |
| Operating Expenses | 105.11M | 136.89M | 185.73M | 228.37M | 148.38M |
| Depreciation & Amortization | 1.54M | 3.68M | 1.84M | 2.13M | 1.7M |
| EBITDA | (95.73M) | (118.85M) | (158.23M) | (205.16M) | (145.09M) |
| EBITDA Margin | -1264.2% | -1227.1% | -10014.4% | — | — |
| Operating Income | (97.54M) | (127.2M) | (184.15M) | (228.37M) | (150.07M) |
| Operating Margin | -1288.1% | -1313.4% | -11654.7% | — | — |
| Interest Income | 272K | 4.67M | 24.08M | 21.09M | 0 |
| Interest Expense | 0 | 791K | 1.27M | 3.02M | 2.56M |
| Other Income / Expenses | 272K | 3.88M | 22.81M | 18.06M | 729K |
| Income Before Tax | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Pre-Tax Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Net Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| EPS (Basic) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| EPS (Diluted) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| Weighted Avg Shares | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
| Weighted Avg Shares (Diluted) | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.